Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of sintilimab plus chemotherapy as neoadjuvant treatment for resectable esophageal cancer
ChiCTR2100050561Phase 4Recruiting
- Sponsor
- Zhangzhou Affiliated Hospital of Fujian Medical University
- Start
- Oct 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of sintilimab in esophageal cancer, sponsored by Zhangzhou Affiliated Hospital of Fujian Medical University. Primary endpoint: Complete pathological remission. Started Oct 2021; status: recruiting.
02
Drugs
sintilimab
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on ChiCTR2100050561.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100050561.